Wouldn't it be nice to see the company invest in businesses and have robust partnerships with distribution partners, doctors and patients, generating revenues of over $1m per month? CGB has been going hard (or so they say) growing the business internationally, spending big on their own salaries year after year, partnerships, mou's, etc. Have we seen sales of Canntab yet? Other players come into the market, like Montu and are smashing it. We have Andrew and his immense wealth of knowledge, seed banks, research, partnerships with Medcan who have the full suite of licences and yet we continue to drag along the bottom.
CGB Price at posting:
0.3¢ Sentiment: None Disclosure: Held
